Genen­tech and Bio­gen roll the dice on an up­start biotech with a new siR­NA ap­proach — go­ing deep in­to the brain for tar­gets in neu­rode­gen­er­a­tion

Ata­lan­ta isn’t your av­er­age stealth biotech mak­ing a de­but. They have some his­to­ry and deals to sketch out in rough out­lines.

The found­ing ex­ecs date the silent launch all the way back to mid-2019, with the pub­li­ca­tion of a sem­i­nal study look­ing at a new siR­NA strat­e­gy for neu­rode­gen­er­a­tion. And in­stead of scout­ing for their first part­ners, the fledg­ling biotech can al­ready count 2 promi­nent play­ers as al­lies in the ex­ten­sive pre­clin­i­cal work that’s been done to es­tab­lish the plat­form.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN